# Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects

> **NCT03303924** · PHASE1 · COMPLETED · sponsor: **Entasis Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ETX2514 and sulbactam

## Key facts

- **NCT ID:** NCT03303924
- **Lead sponsor:** Entasis Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-21
- **Primary completion:** 2017-10-17
- **Final completion:** 2017-10-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303924, "Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03303924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*